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Abstract
A recent review has suggested that bovine thrombin is not associated with an increased risk of
bleeding in surgical populations. In spite of extremely limited evidence available, many valuable
resources (e.g. safety surveillance and post-marketing programs, case reports) were excluded in
reaching this conclusion. While waiting for the adequately powered, controlled clinical trials to
address the effects of bovine thrombin on bleeding and thrombotic events, the potential risk cannot
be simply ignored. Rather, continued vigilance in the post-surgical setting for bleeding events that
may be associated with the development of acquired coagulation factor inhibitors following bovine
thrombin administration is warranted.
A recent review by Reynolds and colleagues examined the
rate of bleeding events in surgical patients using data from
16 clinical studies published and indexed in Medline
from 1997 to 2007 in which risk of bleeding was a pri-
mary or secondary objective [1]. Five additional surgical
studies that evaluated topical thrombin were also
included, although risk of bleeding was not required to be
a primary or secondary endpoint. Based on the defined lit-
erature review, the authors concluded that the risk of
bleeding was not different between patients treated with
bovine thrombin compared with patients in other surgical
populations.
Intractable surgical bleeding is a rare event and its associ-
ation with poor outcome suggests significant under-
reporting. Although rare, this complication has an enor-
mous clinical and financial burden [2]. Based on the cur-
rent published data, it is not possible to draw any
definitive conclusions on the safety of bovine thrombin.
Randomized controlled studies to establish safety are
needed but the required number of subjects is related to
the frequency of the event in question. As such, a huge
number of subjects need to be recruited making this study
almost unattainable.
The available studies cited in this review are indicators of
severely llimited evidence on the safety of topical bovine
thrombin. It is hard to compare the bleeding rates among
independent studies on different patient populations
undergoing various procedures as several factors can play
a role. In the absence of (and waiting for) evidence of
higher quality, we need to draw on any and all available
evidence.
Safety surveillance and/or pharmacovigilance post-mar-
keting programs are a condition of product approval.
Invariably, the safety profile of a marketed product con-
tinuously evolves to reflect accumulated clinical experi-
ence. Despite reduced reliability compared with evidence
from trials, such programs, in addition to published case
reports, are important tools for further identifying and
assessing potential safety concerns. In the case of topical
bovine thrombins and despite very limited available data,
Reynolds et al excluded these resources in their assess-
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ment, resulting in a skewed and deficient evaluation of the
association between use of topical bovine thrombin and
bleeding events. In fact, a boxed warning has been
included in the prescribing information for topical bovine
thrombin based on data from clinical trials, numerous
early sentinel case reports, and post-marketing adverse
event surveillance [3]. This boxed warning describes the
occasional association of abnormalities in hemostasis,
which appear to be related to the formation of bovine
thrombin product antibodies and subsequent cross-reac-
tion with endogenous proteins. These antibodies have
been largely linked to impurities present in bovine
thrombin preparations (e.g. prothrombin, factors V, VII
and X) and recent reports indicate that improved manu-
facturing process can significantly reduce these and other
impurities [4]. Nonetheless, these processes cannot elimi-
nate all impurities [5], and more importantly, even a
hypothetical completely pure bovine thrombin prepara-
tion will still pose some immunogenicity because of spe-
cies-specific epitopes, resulting in production of anti-
bovine antibodies with some degree of of cross-reacting
with human thrombin [6,7].
Although a pharmacoeconomic assessment has not been
conducted, a cursory examination of three recent case
reports suggests that bovine thrombin-associated bleed-
ing events may have a substantial impact on patient out-
comes and institutional costs [8-10]. Interventions
reported in these cases included corticosteroids and intra-
venous immunoglobulin (IVIG) as well as fresh frozen
plasma, platelets and red blood cell transfusion, plas-
mapheresis, vitamin K, recombinant factor VIIa (rFVIIa),
cyclophosphamide, and/or rituximab; thus, the potential
economic impact of an induced coagulopathy associated
with exposure to bovine thrombin may be significant.
Based on the incomplete inclusion of available data and
limitations of the selected clinical trials in their review, we
believe the conclusion determined by Reynolds and col-
leagues is unsubstantiated. Furthermore, in the absence of
large, controlled clinical trials specifically designed and
adequately powered to detect the effect of bovine
thrombin on bleeding and thrombotic risk, the potential
risk cannot be simply ignored. In fact, the presence of risk
associated with bovine thrombin application is not con-
troversial; the question to resolve is what the incidence of
these events in routine surgical practice is. We believe that
for now, the full body of evidence, including clinical trial
results, case studies, rigorous and comprehensive review
articles, and spontaneous adverse event reports, taken col-
lectively supports continued vigilance in the post-surgical
setting for bleeding events that may be associated with the
development of acquired coagulation factor inhibitors.
We believe that the full body of evidence-including clini-
cal trials results, case studies, rigorous and comprehensive
review articles, and spontaneous adverse event reports-
taken collectively, the potential immediate and long-term
costs associated with treating bovine thrombin-induced
coagulopathies make it reasonable and in line with
patients' interests to consider other commercially availa-
ble and less immunogenic forms of thrombin as prudent
alternatives.
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